| 58 | 4 | 15 |
| 下载次数 | 被引频次 | 阅读次数 |
目的:分析光动力疗法联合Lucentis玻璃体腔注射治疗脉络膜新生血管疾病(CNV)的疗效。方法:选取2013年8月~2014年8月在我院接受住院治疗的82例CNV患者作为研究对象,按照随机数表法将所有入组患者分为:对照组(接受光动力疗法治疗)及观察组(接受光动力疗法联合Lucentis玻璃体腔注射治疗),每组各41例。比较两组最佳矫正视力、眼压及视网膜黄斑中央厚度、视野平均敏感度等差异。结果:观察组接受治疗后的视力提高比例显著高于对照组,视力下降比例低于对照组(P<0.05);眼压及视网膜黄斑中央厚度均明显小于对照组(P<0.05);10°及30°视野平均敏感度均高于对照组(P<0.05)。结论:光动力疗法联合Lucentis玻璃体腔注射治疗可以有效提升CNV患者的视力及视敏度,降低眼压及视网膜黄斑中央厚度,是一种理想的治疗方式。
Abstract：Objective:To analyze the efficacy of photodynamic therapy combined with intravitreal injection of Lucentis therapy for choroidal neovascularization(CNV).Methods:A total of 82 cases of patients with CNV admitted to our hospital from August 2013 to August 2014 were selected as research subjects.According to random number table method,all enrolled patients were divided into control group(receiving photodynamic therapy only)and observation group(receiving photodynamic therapy combined with intravitreal injection of Lucentis therapy),with 41 cases in each.Differences in best-corrected visual acuity,intraocular pressure and central macular thickness,mean sensitivity of visual field and so on in two groups were compared.Results:After treatment,visual acuity improvement ratio of observation group was significantly higher than that of control group and visual acuity decrease ratio was lower than that of control group(P<0.05);intraocular pressure and central macular thickness were significantly less than those of control group(P<0.05);mean sensitivity of 10°and 30° visual field was higher than that of control group(P<0.05).Conclusions:Photodynamic therapy combined with intravitreal injection of Lucentis therapy can effectively improve vision and visual acuity of patients with CNV and meanwhile reduce intraocular pressure and central macular thickness,which makes it an ideal treatment method.
1 Ladaique M,Dirani A,Ambresin A.Long-term follow-up of choroidal neovascularization in pathological myopia treated with intravitreal ranibizumab[J].Klin Monbl Augenheilkd,2015,232(4):542-547.
2 王雨生,王海燕.光动力疗法治疗脉络膜新生血管疾病的历程和现状[J].眼科,2010,19(4):217-220.
3 Loutfi M,Siddiqui MR,Dhedhi A,et al.A systematic review and meta-analysis comparing intravitreal ranibizumab with bevacizumab for the treatment of myopic choroidal neovascularisation[J].Saudi J Ophthalmol,2015,29(2):147-155.
4 Adatia FA,Luong M,Munro M,et al.The other CNVM:a review of myopic choroidal neovascularization treatment in the age of anti-vascular endothelial growth factor agents[J].Surv Ophthalmol,2015,60(3):204-215.
5 杜军辉,李夏,成静.光动力疗法联合血管内皮生长因子抑制剂及糖皮质激素治疗脉络膜新生血管疾病的研究进展[J].中华临床医师杂志,2013,7(15):7180-7185.
6 Saitta A,Nicolai M,Neri P,et al.Rescue therapy with intravitreal aflibercept for choroidal neovascularization secondary to choroidal osteoma non-responder to intravitreal bevacizumab and ranibizumab[J].Int Ophthalmol,2015,35(3):441-444.
7 Veloso CE,Schmidt-Erfurth U,Nehemy MB.Choroidal neovascularization induced by immunogenic alteration of the retinal pigment epithelium in dengue fever[J].Case Rep Ophthalmol,2015,6(1):18-23.
8 李晓陵,何守志,王炜,等.Ranibizumab治疗老年黄斑变性合并脉络膜新生血管短期临床观察[J].军医进修学院学报,2011,32(5):438-440.
9 Byon IS,Kwon HJ,Kim SI,et al.Reduced-fluence photodynamic therapy in polypoidal choroidal vasculopathy nonresponsive to ranibizumab[J].Ophthalmic Surg Lasers Imaging Retina,2014,45(6):534-541.
10 金昱,石安娜,石浔,等.三维频域光学相干断层扫描、彩色中心视野对诊治脉络膜新生血管疾病的意义[J].南昌大学学报,2011,51(9):41-43,46.
11 Claxton L,Malcolm B,Taylor M,et al.Ranibizumab,verteporfin photodynamic therapy or observation for the treatment of myopic choroidal neovascularization:cost effectiveness in the UK[J].Drugs Aging,2014,31(11):837-848.
12 罗文彬,游志鹏.光动力疗法联合Lucentis玻璃体腔注射治疗CNV的疗效观察[J].重庆医学,2014,43(31):4213-4215.
13 Sayanagi K,Gomi F,Akiba M,et al.En-face high-penetration optical coherence tomography imaging in polypoidal choroidal vasculopathy[J].Br J Ophthalmol,2015,99(1):29-35.
14 李臻.应用OCT观察Lucentis治疗视网膜静脉阻塞性黄斑水肿的疗效[J].内蒙古医学杂志,2013,45(10):1167-1170.
15 Sakai T,Ohkuma Y,Kohno H,et al.Three-year visual outcome of photodynamic therapy plus intravitreal bevacizumab with or without subtenon triamcinolone acetonide injections for polypoidal choroidal vasculopathy[J].Br J Ophthalmol,2014,98(12):1642-1648.
基本信息:
DOI：10.13210/j.cnki.jhmu.20151203.003
中图分类号:R773.4
引用信息:
[1]苏延梅.光动力疗法联合Lucentis玻璃体腔注射治疗脉络膜新生血管疾病的疗效评估[J].海南医学院学报,2016,22(05):509-511.DOI:10.13210/j.cnki.jhmu.20151203.003.
基金信息:
陕西省卫计委卫生科研项目(2013D172)~~
2015-12-03
2015-12-03
2015-12-03